Search Results

Biocytogen Pharmaceuticals and ABL Bio Inc. today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).

Ablative Solutions, Inc., today announced that the TARGET BP I Pivotal Trial evaluating alcohol-mediated renal denervation with the Peregrine System ™ Kit met its primary endpoint, showing a statistically significant difference in 24-hour Ambulatory Blood Pressure between treatment and sham procedure at 3 months.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).

Ascentage Pharma (6855 HK) announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed Amy Ables, Ph.D . as chief strategy officer of the organization, effective immediately.

Acclaro Medical, a medical technology company that specializes in developing and delivering trailblazing solutions for medical aesthetics and surgical practitioners worldwide, today announced clearance by the U.S. Food and Drug Administration (FDA) for a new indication of the Company’s UltraClear® cold ablative fractional 2910 nm fiber laser.

Able Medical Devices has received U.S. FDA 510(k) clearance for its Valkyrie RIB System further enhancing its cardiothoracic and trauma portfolio.

I-Mab today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380).